US President Donald Trump speaks within the South Courtroom Auditorium of the Eisenhower Govt Workplace Constructing on the White Home in Washington, DC, US, on Thursday, Feb. 5, 2026.
Aaron Schwartz | Bloomberg | Getty Photos
President Donald Trump on Thursday introduced the launch of TrumpRx — a direct-to-consumer web site that’s key to his administration’s efforts to decrease prescription drug prices within the U.S.
The president stated tens of millions of People would lower your expenses by the platform. But it surely’s nonetheless unclear if all sufferers — notably these with insurance coverage protection — will see extra value financial savings from utilizing that website to purchase their medicines than they’d by present strategies. TrumpRx targets people who find themselves prepared to pay with money and forgo insurance coverage, which means that sufferers with or without restricted protection could profit probably the most.
“You are going to save a fortune and that is additionally so good for total well being care,” Trump stated at an occasion Thursday evening unveiling the web site.
The location doesn’t promote medication on to American sufferers, however acts as a central hub that factors them to drugmakers which can be providing reductions on sure merchandise on their very own direct-to-consumer websites, or provides them low cost coupons to take to pharmacies. For instance, Eli Lilly and Novo Nordisk have been already providing their blockbuster weight problems medication at hefty reductions to cash-paying sufferers, even earlier than the reductions Trump touted on Thursday.
Clicking on the platform’s provide for Lilly’s common Zepbound weight reduction injection sends shoppers to the corporate’s LillyDirect platform, the place they’ll order the therapy and submit prescription particulars.
A screenshot of a Zepbound order on the TrumpRx web site.
Preview
Filters
Supply Information
In latest months, Lilly, Novo and not less than 14 different drugmakers have negotiated agreements with the Trump administration to take part on the platform and voluntarily promote sure medicines at a reduction to Medicaid sufferers. These landmark offers are a part of Trump’s broader “most favored nation” coverage, which pushes to hyperlink U.S. drug costs to the bottom ones overseas.
At launch, the positioning options solely medicines from the primary 5 corporations to strike pricing offers with the administration: AstraZeneca, Lilly, EMD Serono, Novo Nordisk and Pfizer, in line with a White Home reality sheet. It’ll listing medication from different corporations “within the coming months,” the administration stated.
The platform is the federal government’s newest effort to attempt to rein in U.S. prescription drug costs, that are two to 3 occasions larger on common than these in different developed nations — and as much as 10 occasions greater than in sure nations, in line with the Rand Corp., a public coverage assume tank.
However TrumpRx “would not seem to be it’s the solely answer” to that challenge for many People, stated Juliette Cubanski, deputy director of this system on Medicare Coverage at KFF, a well being coverage analysis group. The cash-pay choices could possibly be higher offers for sufferers with out insurance coverage, nevertheless it’s tough to evaluate precisely how many individuals stand to profit from TrumpRx, she added.
“In the event that they’re capable of get a drug lined by their insurance coverage at a comparatively inexpensive copay, then there’s not an awesome upside to utilizing the TrumpRx web site,” Cubanski stated.
She stated folks with insurance coverage protection who purchase by direct-to-consumer platforms may additionally not have their purchases depend towards their advantages, which implies it would not assist them meet their deductible or out-of-pocket most.
However Cubanski stated there’s potential for TrumpRx to be useful in increasing entry to sure medication at extra inexpensive costs, notably medicines not lined extensively by insurance coverage within the U.S., reminiscent of weight problems medication. Medicare will begin overlaying weight reduction therapies for the primary time later this 12 months as a part of the offers Lilly and Novo struck with Trump, however many employers are nonetheless hesitant to cowl these medication.
Nonetheless, most of the different merchandise anticipated to be listed on TrumpRx are already extensively lined by insurance coverage, and a few can be found as cheaper generics from competing drugmakers.
Questions on financial savings
Questions stay about how a lot financial savings folks can anticipate in the event that they purchase their medicines at direct-to-consumer costs.
The introduced worth reductions for sure medication are framed as steep cuts from their so-called retail listing costs. For instance, below Novo Nordisk’s settlement with the administration, some doses of its diabetes drug Ozempic can be priced at $350 per thirty days on TrumpRx, which is lower than half of its roughly $1,000 month-to-month listing worth.
However these listing costs are sometimes far larger than what personal insurers and authorities packages in the end pay for medicines after rebates, reductions and different concessions, in line with researchers at Georgetown’s Medicare Coverage Initiative. That means some payers could already be securing costs corresponding to — or decrease than — the newly introduced reductions on medicines below the Trump offers.
The Georgetown researchers cited one research that discovered that common reductions on brand-name medication in Medicare Half D run round 40% of listing costs. In the meantime, reductions in Medicaid exceed 75%, in accordance to a Congressional Finances Workplace research.
Within the personal sector, “we have got insurers and pharmacy profit managers negotiating decrease costs and designing an insurance coverage profit that permits folks to profit from these worth negotiations,” stated KFF’s Cubanski.
“My guess is that for many medication, not less than most brand-name medicines, persons are more likely to get a greater deal utilizing their insurance coverage quite than buying a drug by a direct-to-consumer web site,” she stated.
Medication on TrumpRx
On the launch of the positioning, the administration listed a variety of main medication as accessible for reductions, with a selected emphasis on common GLP-1 merchandise:
- Ozempic injection for diabetes, made by Novo Nordisk: Beginning at $199 per thirty days, down from round $1,000
- Wegovy injection for weight problems, made by Novo Nordisk: Beginning at $199 per thirty days, down from round $1,350
- Wegovy capsule for weight problems, made by Novo Nordisk: $149 per thirty days for the beginning doses
- Zepbound injection for weight problems, made by Eli Lilly: beginning at $299 per thirty days, down from $1,086
The White Home additionally put an emphasis on cash-pay reductions for fertility medication like Gonal-F from EMD Serono, which was listed at $168.
Dozens of different medication that corporations anticipated to be be listed on the platform weren’t as of Thursday evening. These embody key therapies from corporations together with Amgen, Merck and Gilead, amongst others.
In an interview with CNBC at a convention in January, Bristol Myers Squibb CEO Chris Boerner stated the corporate has a number of merchandise on its present direct-to-consumer platform, which first provided a cash-pay low cost on its blood thinner Eliquis. That platform will finally hyperlink to TrumpRx, he stated.
The corporate goes to look at methods to place further merchandise in its portfolio by itself platform, “the place it is sensible,” Boerner added. He stated Bristol Myers is “aligned with the administration” on the problem of the U.S. well being care system being too advanced, and stated a number of middlemen can improve prices.
“What we like about these [direct-to-consumer models], the place they make sense from a enterprise standpoint, is you are capable of circumvent a few of that,” Boerner stated.
In the meantime, in an unique interview with CNBC final week, Eli Lilly CEO Dave Ricks stated the corporate was the primary drugmaker to promote weight problems therapies on to sufferers, and that TrumpRx is “taking that and increasing it throughout the business” to different medicines.
“We’re all for that,” Ricks stated.
